Latest News

Cingulate reports phase 3 safety data for CTx-1301 to treat ADHD in children, adolescentsLatest revision | Image Credit: © Stepan Popov - © Stepan Popov - stock.adobe.com.
Cingulate reports phase 3 safety data for CTx-1301 to treat ADHD in children, adolescents

March 4th 2025

Results will be included an a final analysis of safety and efficacy data for CTx-1301, which will be included in a NDA submission with the FDA, stated Cingulate Inc.

ADHD with ASD and without it: Should they be treated differently? | Image credit: Contemporary Pediatrics
ADHD with ASD and without it: Should they be treated differently?

January 29th 2025

Background on digital therapeutics and what they can do for mental health | Image Credit: © Syda Productions - © Syda Productions - stock.adobe.com.
Digital therapeutics and what they can do for mental health

August 8th 2024

Image Credit: © Artur - © Artur - stock.adobe.com.
Weekly review: ADHD treatment FDA approval, peanut consumption and adolescent tolerance, and more

June 3rd 2024

FDA approves clonidine hydrochloride to treat ADHD in patients 6 years and up | Image Credit: © Calin - © Calin - stock.adobe.com.
FDA approves clonidine hydrochloride to treat ADHD in patients 6 years and up

May 29th 2024

Video Interviews
Podcasts

More News

© 2025 MJH Life Sciences

All rights reserved.